Type Whole antibody Target CD125 Legal status investigational | ATC code none CAS Number 1044511-01-4 | |
 | ||
Benralizumab (INN) is a monoclonal antibody which is being developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).
Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.
References
Benralizumab Wikipedia(Text) CC BY-SA